STOCKS TELEGRAPH

Tag: NK

  • INmune Bio, Inc. (INMB) Stock on the Rise Following First Patient Treatment in INKmune Phase 1 Clinical Trial

    INmune Bio, Inc. (INMB) stock prices were up by 12.67% as of the market closing on July 13th, 2021, bringing the price per share up to USD$26.68. Subsequent premarket fluctuations saw the stock rise by 7.01%, bringing it up to USD$28.55.

    INKmune

    July 12th, 2021 saw the company announce the use of INKmune, its Natural Killer (NK) cell priming platform, had been used to treat the first patient in Phase 1 clinical trial. The treatment is being explored as a viable option for patients with high-risk myelodysplastic syndrome. MDS is a hematopoietic stem cell disorder that is indicated by functionally defective NK cells, with the level of dysfunction being predictive of overall survival. Roughly 33% of MDS cases develop into acute myelogenous leukemia (AML). With no known cure for MDS, existing therapies like chemotherapy and bone marrow/stem cell transplantation have varying degrees of success.

    Research Conducted

    With levels of NK function in MDS patients being predictive of overall survival, 15 years of lab research into potential patient treatment has raised hopes. The enhancement of low-level NK activity in patients with poor prognosis to the level of those with better overall survival, thereby altering the course of the disease, could be highly commercially promising.

    Scope of Research

    Lab work has shown INKmune binding to multiple NK receptors and initiates the activation of more than 3000 genes associated with function, trafficking, proliferation, and overall survival. With not a single cytokine available that has such a myriad of physiological effects, INKmune is being referred to as a psuedokine.

    Expanded Opportunities

    The treatment of the first patient in the trial serves as a major milestone, with the company being the first to study the INKmune platform in a formal clinical setting. With it being widely known that dysfunctional NK cells in cancer patients are not effective at eradicating residual disease after chemotherapy, leading to relapse and poor outcomes. The company has shown that with the delivery of tumor-specific activating signals to NK cells with INKmune, autologous tumor killing can be initiated.

    Future Outlook for INMB

    Armed with the significant milestone of having treated the first patient in the study, INMB is poised to capitalize on the opportunities afforded to it as a result. The company is keen to push for the accelerated development and eventual commercialization and proliferation of the treatment. Current and potential investors are hopefully that management will continue to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.